The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Research Sheds Light on Scleromyxedema, a Rare Skin Disorder

Research Sheds Light on Scleromyxedema, a Rare Skin Disorder

October 18, 2019 • By Larry Beresford

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Lichen myxedematosus and scleromyxedema.

Lichen myxedematosus and scleromyxedema.
Biophoto Associates / Science Source

Scleromyxedema is a rare, mucinous skin disorder of unknown origin, one of a number of conditions that mimic systemic sclerosis. Although cases of scleromyxedema remain rare, a better understanding of its mechanisms of action could have implications for the research and treatment of scleroderma and related autoimmune conditions, says Laura K. Hummers, MD, ScM, co-director of the Scleroderma Center at Johns Hopkins University School of Medicine, Baltimore.

You Might Also Like
  • Fibrotic Diseases of the Retroperitoneum & Skin, & Rare Scleroderma Mimics
  • Pain Management Research Sheds Light on Postsurgical Pain Sensitization, Opioid Risks, Nondrug Interventions
  • Chondrocyte Enlargement Sheds New Light on Cell Volume Regulation
Explore This Issue
October 2019
Also By This Author
  • California Rheumatologists Explore Managed Care, Treatment Options

“We don’t know the actual prevalence of scleromyxedema, in part because rheumatologists don’t always think to look for it,” says Dr. Hummers, corresponding author of an open-label, observational report on 15 patients with scleromyxedema and the impact of intravenous immunoglobulin (IVIG) therapy published in the journal Arthritis Care & Research.1 “When I reviewed the indexed medical literature, I found a total of 200 cases referenced, mostly case reports.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

This potentially life-threatening systemic disorder is associated with profound central nervous system disturbances, including seizures and coma, and can also involve inflammatory polyarthritis, proximal myopathy and gastrointestinal abnormalities. Scleromyxedema has a similar distribution of skin findings as systemic sclerosis, with similar clinical features such as arthritis, Raynaud’s syndrome, skin fibrosis and esophageal dysmotility in some patients.

Scleromyxedema has no approved diagnostic criteria or diagnostic codes. “We don’t know the cause, although it is universally associated with monoclonal proteins. But how that connects with other aspects of the disease is not clear,” Dr. Hummers says. All but one of the 15 patients she studied had monoclonal gammopathy of undetermined significance in their blood plasma.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Franco Rongioletti, MD, chair of the Unit of Dermatology at the University of Cagliari, Italy, and colleagues have also reported on case studies of European scleromyxedema patients and progress in developing diagnostic criteria and lines of treatment.2 They found monoclonal gammopathy in 27 of 30 patients and confirmed that scleromyxedema is a chronic and unpredictable disease with severe systemic manifestations and a guarded prognosis.

Treatment Almost Always Succeeds

“What landed scleromyxedema on my plate at the Scleroderma Center is that we had seen a couple of case reports about its treatment with intravenous immunoglobulin (IVIG). Then we picked up a few patients of our own and successfully treated them with IVIG,” Dr. Hummers tells The Rheumatologist.

But immunoglobulin comes with complications, including potential for blood clotting during treatment. A bigger problem? Its high cost, up to $15,000 per treatment, initially given monthly. “We also need to infuse it very slowly. It takes two to five days, with a home healthcare nurse present, to administer a single dose,” says Dr. Hummers.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Research Reviews Tagged With: intravenous immunoglobulins, IVIg, mimics, ScleromyxedemaIssue: October 2019

You Might Also Like:
  • Fibrotic Diseases of the Retroperitoneum & Skin, & Rare Scleroderma Mimics
  • Pain Management Research Sheds Light on Postsurgical Pain Sensitization, Opioid Risks, Nondrug Interventions
  • Chondrocyte Enlargement Sheds New Light on Cell Volume Regulation
  • Rat Model of Arthritis Sheds Light on How Disease Affects Bone

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.